Biological indicator
View Patent ↗A kinase is used in a biological indicator for validation of treatment processes designed to reduce the amount or activity of a biological agent in a sample. The indication can be used for validation of sterilization treatment. The formation of ATP from a substrate comprising ADP is measured via the liciferin/luciferate system in a luminameter. Thermostable adenylate kinase from sulfolobus acidocaldarius is especially suitable for the validation of procedures to inactivate transmissible spongiform encephalopathy agents.
1. A method for validating a treatment process for reducing the amount or activity of a contaminating biological agent in a sample, comprising:
(i) exposing an indicator and the contaminating biological agent to the treatment process,
wherein the indicator is a thermostable kinase,
the contaminating biological agent comprises at least one member selected from the group consisting of bacteria, viruses, spores, proteins, peptides and prions, and
the treatment process comprises an exposure to at least one member selected from the group consisting of pH, temperature, pressure, enzyme, detergent, chemical sterilant, gas-phase sterilant, and high-temperature autoclaving with steam;
(ii) measuring residual kinase activity of the thermostable kinase after the treatment; and
(iii) comparing said residual kinase activity of the thermostable kinase to the kinase activity of the thermostable kinase before the treatment;
wherein a reduction in the kinase activity of the thermostable kinase after the treatment, as compared to the kinase activity of the thermostable kinase before the treatment, can be correlated with a reduction in the amount or activity of the contaminating biological agent.
2. The method of claim 1 , wherein the thermostable kinase is immobilised as part of a solid support.
3. The method of claim 1 , wherein the thermostable kinase comprises adenylate kinase, acetate kinase or pyruvate kinase.
4. The method of claim 2 , wherein the solid support comprises an indicator strip, a dip stick or a bead.
5. The method of claim 1 , wherein the contaminating biological agent comprises a transmissible spongiform encephalopathy.
6. The method of claim 1 , wherein the thermostable kinase has an amino acid sequence selected from the group consisting of SEQ ID Nos:1-25.
7. The method of claim 1 , wherein the thermostable kinase is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID Nos:26-30.
8. A method for validating a treatment process, comprising:
(i) obtaining a sample that may contain a contaminating biological agent, wherein the contaminating biological agent comprises at least one member selected from the group consisting of bacteria, viruses, spores, proteins, peptides and prions; and
(ii) exposing a mixture comprising the sample and a defined amount of a thermostable kinase to the treatment process, wherein the treatment process comprises an exposure to at least one member selected from the group consisting of pH, temperature, pressure, enzyme, detergent, chemical sterilant, gas-phase sterilant, and high-temperature autoclaving with steam; wherein the treatment process reduces an amount or activity of the contaminating biological agent;
(iii) measuring a residual kinase activity and optionally calculating a reduction in kinase activity; and
(iv) comparing said residual kinase activity to a predetermined kinase activity, or comparing said reduction in kinase activity to a predetermined reduction in kinase activity, wherein the predetermined kinase activity or predetermined reduction in kinase activity corresponds to a confirmed reduction in the amount or activity of the contaminating biological agent under identical treatment process conditions.
9. The method of claim 8 , wherein the infectious contaminating biological agent comprises a transmissible spongiform encephalopathy.
10. The method of claim 8 , wherein the thermostable kinase comprises an adenylate kinase, an acetate kinase or a pyruvate kinase.
11. The method of claim 8 , wherein the thermostable kinase has an amino acid sequence selected from the group consisting of SEQ ID Nos:1-25.
12. The method of claim 8 , wherein the thermostable kinase is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID Nos:26-30.
13. A method of correlating the reduction in the amount or activity of a contaminating biological agent in a sample with the thermostable kinase activity of a biological process indicator, comprising:
(i) preparing a first sample comprising a defined amount of the contaminating biological agent and a second sample containing a defined amount of a thermostable kinase;
(ii) subjecting the first and second samples to a treatment process comprising an exposure to at least one member selected from the group consisting of pH, temperature, pressure, enzyme, detergent, chemical sterilant, gas-phase sterilant, and high-temperature autoclaving with steam;
(iii) measuring the residual kinase activity of the thermostable kinase and optionally calculating the reduction in kinase activity;
(iv) measuring residual amount or activity of the contaminating biological agent and optionally calculating the reduction in the amount or activity of the contaminating biological agent; and
(v) repeating steps (i) to (iv), wherein at least one parameter of the treatment process is changed;
wherein the contaminating biological agent comprises at least one member selected from the group consisting of bacteria, viruses, spores, proteins, peptides and prions.
14. The method of claim 13 , wherein the contaminating biological agent comprises a transmissible spongiform encephalopathy.
15. A method for validating a treatment process for reducing the amount or activity of a contaminating biological agent in a sample, comprising:
(i) directly exposing an indicator and the contaminating biological agent to the treatment process,
wherein the indicator is a thermostable kinase,
the contaminating biological agent comprises at least one member selected from the group consisting of bacteria, viruses, spores, proteins, peptides and prions, and
the treatment process comprises an exposure to at least one member selected from the group consisting of pH, temperature, pressure, enzyme, detergent, chemical sterilant, gas-phase sterilant, and high-temperature autoclaving with steam;
(ii) measuring residual kinase activity of the thermostable kinase after the treatment; and
(iii) comparing said residual kinase activity of the thermostable kinase to the kinase activity of the thermostable kinase before the treatment;
wherein a reduction in the kinase activity of the thermostable kinase after the treatment, as compared to the kinase activity of the thermostable kinase before the treatment, can be correlated with a reduction in the amount or activity of the contaminating biological agent.
16. A method for validating a treatment process, comprising:
(i) obtaining a sample that may contain a contaminating biological agent, wherein the contaminating biological agent comprises at least one member selected from the group consisting of bacteria, viruses, spores, proteins, peptides and prions; and
(ii) directly exposing a mixture comprising the sample and a defined amount of a thermostable kinase to the treatment process, wherein the treatment process comprises an exposure to at least one member selected from the group consisting of pH, temperature, pressure, enzyme, detergent, chemical sterilant, gas-phase sterilant, and high-temperature autoclaving with steam; wherein the treatment reduces an amount or activity of the contaminating biological agent;
(iii) measuring a residual kinase activity and optionally calculating a reduction in kinase activity; and
(iv) comparing said residual kinase activity to a predetermined kinase activity, or comparing said reduction in kinase activity to a predetermined reduction in kinase activity, wherein the predetermined kinase activity or predetermined reduction in kinase activity corresponds to a confirmed reduction in the amount or activity of the contaminating biological agent under identical treatment process conditions.
17. A method of correlating the reduction in the amount or activity of a contaminating biological agent in a sample with thermostable kinase activity of a biological process indicator, comprising:
(i) preparing a first sample comprising a defined amount of the contaminating biological agent and a second sample containing a defined amount of the thermostable kinase;
(ii) subjecting the first and second samples to a treatment comprising direct exposure to at least one member selected from the group consisting of pH, temperature, pressure, enzyme, detergent, chemical sterilant, gas-phase sterilant, and high-temperature autoclaving with wet or dry steam;
(iii) measuring the residual kinase activity of the thermostable kinase and optionally calculating the reduction in kinase activity;
(iv) measuring residual amount or activity of the contaminating biological agent and optionally calculating the reduction in the amount or activity of the contaminating biological agent;
(v) repeating steps (i) to (iv), wherein at least one of the treatment parameters is changed; and
wherein the contaminating biological agent comprises at least one member selected from the group consisting of bacteria, viruses, spores, proteins, peptides and prions.
18. The method of claim 15 , wherein the contaminating biological agent comprises a transmissible spongiform encephalopathy.
19. The method of claim 15 , wherein the thermostable kinase has an amino acid sequence selected from the group consisting of SEQ ID Nos:1-25.
20. The method of claim 15 , wherein the thermostable kinase is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID Nos:26-30.
21. The method of claim 16 , wherein the contaminating biological agent comprises a transmissible spongiform encephalopathy.
22. The method of claim 16 , wherein the thermostable kinase comprises an adenylate kinase, an acetate kinase or a pyruvate kinase.
23. The method of claim 17 , wherein the contaminating biological agent comprises a transmissible spongiform encephalopathy.